Air-Liquid Interface Lung Model for Respiratory Drug Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current in vitro models for studying respiratory diseases, particularly those affecting the human alveolar epithelium, are limited in their ability to replicate human lung physiology and are not scalable or reproducible, making them inadequate for high-throughput drug screening.
Innovation Solution
A high-throughput in vitro lung injury model using a 96-well transwell system seeded with primary human alveolar epithelial cells, which mimics the human alveolar epithelium by maintaining tight junction integrity and allowing for the study of respiratory pathogens and therapeutic compounds.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If submerged cultures of human lung epithelial cells are used, then the model is simple to establish, but it fails to replicate human lung physiology accurately
Solution Approach 1:
The patent transitions from two-dimensional submerged cultures to three-dimensional air-liquid interface cultures in transwell systems. This dimensional change allows the apical surface of epithelial cells to be exposed to air while the basolateral surface remains in liquid medium, accurately replicating the in vivo lung epithelium environment and improving physiological relevance without significantly complicating the model establishment process.
Solution Approach 2:
The patent applies different culture conditions to different surfaces of the epithelial cell monolayer. The apical surface is maintained in an air-exposed environment with specific medium composition, while the basolateral surface is maintained in liquid medium with different composition. This local differentiation of culture conditions enables the model to replicate the heterogeneous physiological environment of lung epithelium more accurately.
2Reliability
If transwell systems with air-liquid interfaces are used, then human lung physiology is better mimicked, but the system complexity increases
Solution Approach 1:
The patent employs standard transwell insert systems that are commercially available and can be used for multiple purposes including drug screening, toxicity testing, and physiological studies. This multi-functionality allows the same basic platform to address various research questions without requiring separate specialized equipment for each application, thereby limiting the increase in system complexity.
Solution Approach 2:
The patent divides the culture system into distinct compartments (apical and basolateral chambers) separated by a porous membrane. This segmentation allows independent control and optimization of culture conditions in each compartment while using a relatively simple transwell insert structure, balancing physiological relevance with system simplicity.
3Productivity
If immortalized cell lines such as A549 cells are used, then the model is reproducible and scalable, but key physiological features are not reproduced due to phenotypical differences
Solution Approach 1:
The patent changes the key parameter of cell origin from immortalized cell lines to primary human alveolar epithelial cells. This parameter change fundamentally alters the phenotypical characteristics of the cells, enabling them to reproduce key physiological features such as proper tight junction formation, ion channel expression, and response to respiratory pathogens, while still maintaining scalability through standardized culture protocols.
Solution Approach 2:
The patent uses a composite approach by combining primary human alveolar epithelial cells with transwell support structures and specialized culture media. This composite system leverages the physiological accuracy of primary cells while using the transwell framework and optimized media to ensure reproducibility and scalability, effectively combining the advantages of both immortalized cell lines and primary cells.
4Reliability
If non-diseased human primary alveolar cells are used in sufficient quantities, then physiological accuracy is improved, but the cost and availability are limited
Solution Approach 1:
The patent performs preliminary expansion and characterization of primary human alveolar epithelial cells before they are needed for experiments. Cells are harvested from lung tissue, expanded in culture under optimized conditions, and characterized for physiological markers in advance. This preliminary action ensures sufficient cell quantities are available for high-throughput screening while maintaining their physiological accuracy, reducing the need for repeated tissue harvesting.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This model enables efficient and scalable screening of therapeutic compounds for respiratory infectious diseases by accurately mimicking human lung physiology, reducing the need for primary cells, and facilitating patient-specific drug treatments.
Implementation Method 1
The tight junction integrity of the alveolar epithelial cells is monitored by measuring transepithelial electrical resistance ( TEER). The TEER is maintained at a value of at least 2000 Ω/cm2.
Implementation Method 2
The AFC is measured as a function of the concentration of fluorescence-labeled dextran present in the apical chamber after a 24-hour incubation period.
Implementation Method 3
The APP is measured using fluorescence-labeled dextran with a molecular weight of 70 kDa.
Data Source
AI summary
The present invention relates to a physiologically relevant, high-throughput in vitro human lung injury model used for studying therapeutic interventions against severe respiratory pathogens. In this model, human alveolar epithelial cells are infected with the highly pathogenic influenza A virus A/HK/483/97 (H5N1) and subsequently treated with extracellular vesicles (EVs) 24 hours post-infection. Influenza A(H5N1) infection significantly reduces alveolar fluid clearance (AFC) and increases alveolar permeability (APP) after 24 hours. The administration of therapeutic EVs restores both AFC and APP in vitro, reduces the expression of dysregulated proinflammatory cytokines, and enhances virus-suppressed alveolar sodium and chloride transporters in the infected epithelial cells. These findings demonstrate the potential therapeutic efficacy of EVs in alleviating epithelial damage caused by influenza A(H5N1) and underscore the applicability of the high-throughput lung model for screening treatments for respiratory diseases.